Infrastructure that translates into healthcare access.
What the deployment produced in the field, with the method and the limits printed next to the numbers rather than in a footnote.
What has happened at the counter.
- People screened
- 15K+
- Health alerts generated
- 3,500+
- Conjunctival screenings
- 2,000+
- Share of women among beneficiaries
- ~55%
What each of those numbers is a count of.
Measurement
A physiological measurement is taken with a device the pharmacy already has.
Risk identification
The measurement identifies whether the person may be at risk. It concludes nothing about their health.
Health alert
When a threshold is crossed, an alert is raised for the pharmacy staff, in plain language.
Referral
The person is directed to a health professional, with what was measured and when.
Confirmatory testing
The professional decides. Confirmation, diagnosis and care stay entirely with them.
A screening is a measurement. An alert is a threshold crossed. A suspected case is a person referred for confirmatory testing. None of the three is a diagnosis, and we count no diagnoses.
The anaemia case, stated precisely.
Camera-based conjunctival screening can help identify individuals who may benefit from confirmatory anaemia testing, with particular relevance in settings where laboratory access is limited.
Why it matters where it happens: a person who would not travel to a laboratory will still visit a pharmacy. ~550 people were identified as possibly benefiting from confirmatory testing, and ~55% of the people reached were women — a population where anaemia is both common and routinely missed.
And the part that keeps it running.
- 2025 revenue
- €350K
Health impact that depends on a grant ends with the grant. This figure is here because it is the reason the deployment is still running.
Method, and what these figures are not.
- Internal figures. Everything on this page is counted by AZ54 in its own systems and in the field. No third party has audited them.
- No clinical validation. There is no formal clinical documentation behind the screening measurements, and we make no claim of clinical validity.
- No outcome claim. We count screenings, alerts and referrals. We do not know, and do not claim, how many people were subsequently treated.
- Counts are not deduplicated across modules. Financial services users and people screened are separate counts of separate activities, and must never be added together.
Access, as a consequence of infrastructure.
If your network could produce numbers like these, that is the conversation.